EPRX.TO · Eupraxia Pharmaceuticals Inc.
Canada · RS rating 41 · As of 2026-10-14
| Price | 9.36 CAD |
|---|---|
| 1-day change | -2.4% |
| RS rating (overall / 1M / 3M / 12M) | 41 / 19 / 75 / 57 |
| Stage | Basing |
| Composite / Minervini / CANSLIM score | 31 / 28 / 31 |
| Industry group (rank) | Medical-Biomed/Biotech (54) |
| EPS growth Q/Q | +0.0% |
| Sales growth Q/Q | – |
| Distance from 52-week high | +27.9% |
| Market cap (USD) | $493.7M |